Abstract. Fetal and neonatal exposure to diethylstilbestrol (DES) is known to cause many abnormalities, such as cancer, in the male and female reproductive tracts later in life, and epigenetic mechanisms, such as DNA methylation, may be involved in these processes. In the present study, newborn C57BL/6 male mice were exposed to 3 µg of DES from postnatal days 1 to 5. Subsequently, the expression levels of the DNA methyltransferases Dnmt1, Dnmt3a and Dnmt3b and the transcription factors Sp1 and Sp3, which have been reported to regulate the expression of Dnmts, were examined at days 5, 14 and 30. Furthermore, restriction landmark genomic scanning (RLGS), which can analyze genome-wide DNA methylation, was performed to clarify whether or not aberrant DNA methylation was present in the epididymis of the DES-treated mice at day 30. Increased expression of Dnmt3b was observed at days 5 and 14, followed by increased expression of Dnmt1 and Dnmt3a at day 30, as evaluated by real-time RT-PCR. The expression of Sp1 was also increased at day 30. The RLGS analysis revealed that 7 loci of the genomic DNA were demethylated and 1 locus was methylated in the epididymis of the DES-treated mice. Four of these loci specifically demethylated in DES-treated mice were cloned, and all were found to be located within CpG islands near genes. In conclusion, our results indicated the possibility that DES-induced abnormalities of reproductive organs are associated with altered expression levels of DNA methyltransferases and DNA methylation. THE synthetic estrogen diethylstilbestrol (DES) was prescribed to pregnant women to prevent miscarriage from the 1930s through to the 1970s. However, in 1971, a correlation between DES exposure of mothers and the occurrence of vaginal clear cell carcinoma in their daughters was reported [1]. Subsequently, many other problems of reproductive organs, such as malformations and dysfunctions, were reported to be associated with exposure to DES [2]. Studies using murine models revealed that DES induces similar reproductive abnormalities in mice [3][4][5], and DES is now widely used in a model for estrogenic endocrine disruptors. Our previous studies revealed that mice treated neonatally with DES or other endocrine disruptors show increased or decreased expression levels of various genes in the epididymis or testes, even in adulthood [6][7][8][9]. Since these changes in gene expression last for a long